(Q44761971)

6 December 2017

A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation (English)

1 reference

multicenter clinical trial

6 December 2017

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

F Vincenti

1

1 reference

6 December 2017

R Mendez

2

1 reference

6 December 2017

M Pescovitz

3

1 reference

6 December 2017

P R Rajagopalan

4

1 reference

6 December 2017

A H Wilkinson

5

1 reference

6 December 2017

K Butt

6

1 reference

6 December 2017

D Laskow

7

1 reference

6 December 2017

D P Slakey

8

1 reference

6 December 2017

M I Lorber

9

1 reference

6 December 2017

J P Garg

10

1 reference

6 December 2017

M Garovoy

11

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

American Journal of Transplantation

6 December 2017

1 reference

6 December 2017

7

1 reference

6 December 2017

7

1 reference

6 December 2017

1770-1777

1 reference

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

6 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Increased impact of acute rejection on chronic allograft failure in recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Cardiovascular toxicities of immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

What's in the pipeline? New immunosuppressive drugs in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Transplant tolerance: converging on a moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Adhesion receptors in lymphocyte activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

A single-centre experience of post-renal transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01845.X

10.1111/J.1600-6143.2007.01845.X

21 January 2018

Identifiers

DOI

1 reference

release_72lgt63acrdqxgrzmwjafiaxf4

6 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/72lgt63acrdqxgrzmwjafiaxf4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference